#1COPYRIGHT © ABCELLERA CORPORATE OVERVIEW JPM Healthcare Conference 2024 AbCellera#2JPM HEALTHCARE CONFERENCE 2024 COPYRIGHT © ABCELLERA 2 DISCLAIMER This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "may,” “will,” “could," "would," "should,” “expect,” “intend,” “plan,” "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.#3JPM HEALTHCARE CONFERENCE 2024 COPYRIGHT © ABCELLERA 3 The most important drivers of productivity in drug development are: New insights into the biology of disease Novel solutions to challenging problems.#4JPM HEALTHCARE CONFERENCE 2024 COPYRIGHT © ABCELLERA 4 We have built an engine to generate first-in-class and best-in-class antibody medicines. Build a competitive advantage Investments in technological capability can improve the productivity of drug development. So you can solve hard problems Long-term value creation comes from being able to repeatedly deliver first-in- class and best-in-class products.#5JPM HEALTHCARE CONFERENCE 2024 COPYRIGHT © ABCELLERA 5 OVERVIEW AbCellera's engine is broadly applicable within the $400B¹ antibody therapeutics market. ● ● ● 11+ years of investment in technology, teams, and infrastructure Vertical integration from concept to clinic Validated on 100+ therapeutic programs Leading capabilities on difficult targets and bispecifics Capitalization $1B+* Technology & Infrastructure $500M+ ~600 in liquidity $200M+ from non- dilutive government funding $800M+ in total cash, equivalents, and marketable securities + platform 1 investments employees across 3 countries engine for end-to-end discovery, devel ent & clinical manufacturing ¹Market Size by 2030 Source: IQVIA Portfolio of Partnered Programs 110* 10 12¹ Portfolio of Internal Programs 2 partner-initiated discovery program starts** * As of September 30, 2023; t As of December 31, 2022 molecules in the clinic internal program starts assets in IND- ** With downstream participation#6JPM HEALTHCARE CONFERENCE 2024 COPYRIGHT © ABCELLERA 6 OUR PARTNERS We are increasingly focused on strategic partnerships. We look for partnerships that bring new insights into novel biology or access to unique capabilities to create opportunities in therapeutic areas of shared interest. Lilly AbbVie REGENERON & NOVARTIS Incyte EMPIRICO Therapeutics Prelude THERAPEUTICS > > Expanding relationships with large pharma and large biotech T-cell engager platform deals in oncology and autoimmune conditions Co-development to access new targets and technology > Company creation with top-tier venture capital groups#7JPM HEALTHCARE CONFERENCE 2024 COPYRIGHT © ABCELLERA 7 OUR PIPELINE Advancing an internal pipeline of potential first-in-class and best-in-class assets is a top priority to drive growth. MOLECULE ABCL575 IND-ENABLING ABCL635 IND-ENABLING TARGET OX40L undisclosed GPCR or ion channel INDICATION atopic dermatitis undisclosed First two IND submissions anticipated in 2025. We intend to take additional first-in-class development candidates into IND-enabling studies in 2024 and 2025. $220M in non-dilutive funding from governments of Canada and British Columbia. THERAPEUTIC AREA immunology & inflammation metabolic & endocrine conditions POTENTIAL DIFFERENTIATION best in class first in class#8JPM HEALTHCARE CONFERENCE 2024 COPYRIGHT © ABCELLERA 8 OUR PIPELINE - ABCL575 ABCL575 is a potential best-in-class and second-in-class antibody therapy for the treatment of atopic dermatitis. 1. Croft M, et al. (2009) Immunol Rev. 229(1):173-91. 2. https://clinical trials.gov/search?intr-Amlitelimab 3. https://clinical trials.gov/search?intr-IMG-007 4. https://clinicaltrials.gov/search?intr-%20SAR-442970 Molecule Status Target MOA Indication Therapeutic Area Market Opportunity Potential Differentiation Summary ABCL575 IND-enabling studies (Preclinical) OX40 ligand (OX40L) Blocking and non-depleting Atopic dermatitis (AD) Other indications in autoimmunity and inflammation Immunology & inflammation ● ● $17B by 2032* ABCL575 has been designed with potency, pharmacokinetics, and developability to enable less frequent dosing, which provides a potential for differentiation. Targeting OX40L has the potential to address a broad range of inflammatory conditions and autoimmune diseases, some of which include colitis/inflammatory bowel disease (IBD), asthma/atopy, and diabetes¹. OX40L blocking is currently under investigation for atopic dermatitis², asthma², alopecia areata³, hidradenitis suppurativa (HS)4. *Source: IQVIA#9JPM HEALTHCARE CONFERENCE 2024 COPYRIGHT © ABCELLERA 9 OUR PIPELINE - ABCL635 A potential first-in-class antibody therapy for metabolic and endocrine conditions. ABCL635 is the first AbCellera-led asset derived from our GPCR and ion channel platform. Molecule Status Target MOA Indication Therapeutic Area Market Opportunity Potential Differentiation Summary ABCL635 IND-enabling studies (Preclinical) Undisclosed - GPCR or ion channel Antagonist Undisclosed Metabolic & endocrine conditions >$2B First-in-class Program details and indication will only be disclosed once the molecule reaches the clinic.#10JPM HEALTHCARE CONFERENCE 2024 COPYRIGHT © ABCELLERA 10 OUR ENGINE: T-CELL ENGAGER PLATFORM Continued progress and differentiation for T-cell engager platform. T-cell engagers have tremendous potential for the treatment of cancer and autoimmune conditions but are technically challenging to design and engineer. AbCellera's T-cell engager platform combines unique discovery capabilities, bispecific engineering, and a panel of hundreds of diverse CD3-binding antibodies to potentially: Improve the safety profile of T-cell engagers by creating bispecific antibodies that achieve potent tumor killing with reduced cytokine release, which can help address dose-limiting toxicity. Expand the accessible target space for T-cell engagers in solid tumors by enabling discovery of antibodies that are highly specific to MHC-peptide complexes.#11JPM HEALTHCARE CONFERENCE 2024 COPYRIGHT ABCELLERA 11 OUR ENGINE: T-CELL ENGAGER PLATFORM Reducing dose-limiting toxicity associated with cytokine release. Selection of CD3 binders that achieve potent cell killing with very low cytokine release on an undisclosed target. Example molecule Potent tumor-cell killing % Tumor-cell killing 100- 80- 9 40- 20- • 10 - 0 10-6 10-510-4 10-3 10-2 10-1 100 101 10² Concentration (nM) Low cytokine release TNFa (pg/mL) 600- 500- 400- 300- 200- 100- e . ● • 106 105 10-4 10-3 10-2 101 100 10¹ 10² Concentration (nM) AbCellera molecule Clinical benchmark 1 Clinical benchmark 2#12JPM HEALTHCARE CONFERENCE 2024 COPYRIGHT © ABCELLERA 12 OUR ENGINE: T-CELL ENGAGER PLATFORM Expanding the target space: Discovery platform enables generation of diverse and highly specific pMHC binders. Example molecules 2 pMHC + Fab side view 1 Heavy chain PMAGE-A4230-239 MHC-I Light chain 3 Tumor-cell 100₁ killing (%) 50- 400₁ TNFa (pg/mL) 300- 200- IFNY (pg/mL) 100- 0- 2x105- 1x105- -6 1 -4 O [bispecific] (nM) -2 2 -6 -4 2 -2 2 -6 -4 3 -2 O NL 2 MAGE-A4+ cells AbCellera molecules Molecule R MAGE-A4 knockout cells AbCellera molecules O Molecule R#13JPM HEALTHCARE CONFERENCE 2024 COPYRIGHT © ABCELLERA 13 SUMMARY Continued focus on high-value programs and strategic partnerships. With our differentiated technology position and $1B+ in liquidity, we have a long cash runway for focused strategic investment and execution. Completion of Engine Over the next 2 years we will continue to invest in the final stage of our engine, including construction and commissioning of our manufacturing facility. Our Portfolio of Partnered Programs In 2024, we anticipate partnership deals from our T-cell engager platform. Our partnership strategy is to focus on select high value strategic partnerships, not deal volume. Our Portfolio of Internal Programs We expect ABCL575 and ABCL635 to enter clinical development in 2025. In 2024n and 2025, we expect additional first-in-class development candidates from our GPCR and ion channel platform.#1414 COPYRIGHT © ABCELLERA JPM HEALTHCARE CONFERENCE 2024 YOU THANK